Approval of Alzheimer's Drug ‘Donanemab’ Brings Positive Outlook for Duchembio
The FDA approval of Eli Lilly's 'Donanemab' (marketed as Kisunla), the third Alzheimer's treatment globally, is anticipated to…
Duchembio
1 개의 기사가 있습니다.